Apogee Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Apogee Therapeutics Inc 's ROA in the second quarter of 2026?
Apogee Therapeutics Inc recorded a cumulative net loss of $-294 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -28.05%.

However, within the Healthcare sector 412 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3658, from total ROA ranking in the first quarter of 2026 at 4357.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	108.1 %	83.68 %	25.63 %	-19.31 %	-18.75 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-294	-275	-256	-254	-238
Return On Assets (TTM)	-28.05 %	-31.41 %	-35.2 %	-37.36 %	-33.19 %
APGE's Total Ranking	# 3658	# 4357	# 3862	# 3833	# 3789
Total Assets (TTM) in million	1,349	1,294	937	618	648
Seq. Total Assets Change	4.29 %	38.04 %	51.7 %	-4.71 %	-7.95 %
Seq. Net Income Change	-	-	-	-	-

APGE's 5 Years Annual ROA >> Back to APGE Management Effectiveness >> Compare APGE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 42
Sector	# 413
Overall	# 3578

Return On Assets Statistics
High	Average	Low
-23.1 %	-39.96 %	-75.58 %
(Dec 31 2024)		(Jun 30 2024)

News about Apogee Therapeutics Inc Return on Assets ROA

Apogee Therapeutics Set to Showcase Promising Results from APG777 Phase 2 Trial at EADV 2025

In a significant development for the treatment of moderate-to-severe atopic dermatitis, Apogee Therapeutics, Inc. (Nasdaq: APGE) has announced the acceptance of late-breaking data from its Phase 2 APEX trial of APG777 for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress, set to take place in Paris from September 17 to 20, 2025. This landmark congress, renowned for sharing innovative therapeutic advances, will serve as a platform for Apogee to highlight APG777 s promising potential as a best-in-class biologic treatment for patients struggling with this challenging skin condition.The Phase 2 APEX trial, which has garnered considerable attention, successfully completed enrollment ahead of schedule, surpassing its target by enrolling 123 patients in Part A of the trial. These results encompass a critical evaluation of APG777 s efficacy and safety profile, and the late-breaking presentation at EADV will provide an opportunity for Apogee to share insights into how this novel therapeutic candidate may address the unmet needs of individuals with atopic dermatitis.

- The landscape of therapeutic interventions for respiratory and inflammatory c...

Title : Advancements in Respiratory Therapeutics: Apogee Therapeutics Doses First Participants in Phase 1 Clinical Trial of APG333 The landscape of therapeutic interventions for respiratory and inflammatory conditions has witnessed a significant advancement with the recent announcement by Apogee Therapeutics Inc. (NASDAQ: APGE) regarding the initiation of dosing in their Phase 1 clinical trial of APG333, a novel half-life extended antibody targeting thymic stromal lymphopoietin (TSLP). This pivotal trial aims to assess the safety and pharmacokinetics of APG333 in healthy volunteers, setting the stage for future explorations into its efficacy across a range of respiratory and broader immunological and inflammatory conditions. Respiratory diseases, characterized by chronic inflammation and immune dysregulation, remain a leading cause of morbidity and mortality worldwide. Among the various factors implicated in these conditions is TSLP, a cytokine involved in the regulation of immune responses. Apogee Therapeutics has developed APG333, a unique half-life extended TSLP antagonist that promises to mitigate the inflammatory responses central to respiratory ailments and potentially other immune-related conditions.

Financial Statements
Apogee Therapeutics Inc 's Assets	$ 1,349 million	APGE's Balance sheet
Apogee Therapeutics Inc 's Income	$ -86 million	Quarterly APGE's Income Statement
APGE's Income by Division		See APGE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	FY	FY
Y / Y Total Assets Change	49.16 %	61.75 %	-	-	-
Total Assets in million	1,110	744	460	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-256	-182	-84	0	0
Annual Return On Assets	-23.05 %	-24.48 %	-18.26 %	-	-

APGE's 5 Years Annual ROA >> Back to APGE Management Effectiveness >> Compare APGE ROA to its Competitors

More Return On Assets Ratios
APGE's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
APGE's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for APGE's Competitors
Subscribers only: Roa for Apogee Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for APGE's Customers

You may also want to know
APGE's Roi	APGE's Inventory Turnover Ratio	APGE's Growth Rates	APGE's Dividend Comparisons
	APGE's Profitability Ratios	APGE's Asset Turnover Ratio	APGE's Dividend Growth
APGE's Roe	APGE's Valuation Ratios	APGE's Financial Strength Ratios	APGE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:42:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.